Mary S. Campbell
- Virology top 2%
- HIV Research and Treatment 11
- Infectious Diseases top 5%
- HIV/AIDS Research and Interventions 10
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 5
- CAR-T cell therapy research 3
- Genetics top 5%
- Surgery top 5%
- Bladder and Urothelial Cancer Treatments 11
- Urinary and Genital Oncology Studies 10
- Esophageal Cancer Research and Treatment 5
-
- Sex work and related issues 4
- Co-authors
- Jonathan E. RosenbergDaniel P. PetrylakYohann LoriotJae‐Lyun LeeChunzhang WuMaria MatsangouNobuaki MatsubaraThomas Powles
- Cited by
- VirologyInfectious DiseasesOncology
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (4 papers)Blood (5 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Mary S. Campbell
39 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Virology 328
- Infectious Diseases 542
- Oncology 752
- Genetics 206
- Surgery 742
Countries citing papers authored by Mary S. Campbell
This map shows the geographic impact of Mary S. Campbell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary S. Campbell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary S. Campbell more than expected).
Fields of papers citing papers by Mary S. Campbell
This network shows the impact of papers produced by Mary S. Campbell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary S. Campbell. The network helps show where Mary S. Campbell may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mary S. Campbell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 20 | |
| 2 | 2021 | 6 | |
| 3 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialbreakdown → | 2021 | 175 |
| 4 | 2021 | 1 | |
| 5 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinomabreakdown → | 2021 | 670 |
| 6 | 2020 | 10 | |
| 7 | 2019 | 9 | |
| 8 | 2017 | 230 | |
| 9 | 2015 | 21 | |
| 10 | 2013 | 10 | |
| 11 | 2012 | 34 | |
| 12 | 2012 | 16 | |
| 13 | 2012 | 20 | |
| 14 | 2011 | 66 | |
| 15 | 2010 | 137 | |
| 16 | 2009 | 44 | |
| 17 | 2007 | 35 | |
| 18 | 2006 | 4 | |
| 19 | 2000 | 58 | |
| 20 | 2000 | 17 |
About Mary S. Campbell
Mary S. Campbell is a scholar working on Virology, Infectious Diseases and Hematology, having authored 39 papers that have together received 2.2k indexed citations. Recurring topics across this work include HIV Research and Treatment (11 papers), Bladder and Urothelial Cancer Treatments (11 papers), HIV/AIDS Research and Interventions (10 papers), Urinary and Genital Oncology Studies (10 papers), Cancer Immunotherapy and Biomarkers (5 papers), Esophageal Cancer Research and Treatment (5 papers), Sex work and related issues (4 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Virology (328 citations), Infectious Diseases (542 citations) and Oncology (752 citations). Mary S. Campbell has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Jonathan E. Rosenberg, Daniel P. Petrylak, Yohann Loriot, Jae‐Lyun Lee, Chunzhang Wu, Maria Matsangou, Nobuaki Matsubara, Thomas Powles, Christof Vulsteke and Guru Sonpavde. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.